CDC advisers meet on J&J vaccine recommendation

J&J Says 1:11 Booster Shots Needed

(CNN) -

Vaccine advisers from the U.S. Centers for Disease Control and Prevention (CDC) meet Thursday to review the benefits and risks of the Johnson & Johnson vaccine. against covid-19.

The Advisory Committee on Immunization Practices is expected to vote on the recommendation for use of the vaccine.

According to an agenda posted online Wednesday, the group will attend presentations on thrombosis and thrombocytopenia syndrome, known as TTS, a rare but serious type of blood clot that has been linked to the vaccine, as well as risk assessment. and benefits of the vaccine.

The CDC has said for months that the known and potential benefits of the J&J vaccine outweigh the known and potential risks.

However, he says, women under the age of 50 should be aware of the rare but higher risk of TTS, which involves blood clots with low platelets.

Safety monitoring has been ongoing since the adverse event was first identified in April.

The Johnson & Johnson single-dose vaccine is licensed for use in individuals 18 years of age and older, and can be used as a booster vaccine for adults fully vaccinated with the J&J, Pfizer, or Moderna vaccines.

J&J asks FDA clearance for booster vaccine 0:35

Vaccine counselors will also hear a presentation on vaccine safety in children ages 5 to 11.

advertising

J&J acknowledged that the U.S. Food and Drug Administration updated its vaccine information Tuesday to indicate that people with a history of TTS should not receive Johnson & Johnson's Janssen covid-19 vaccine.

Johnson & Johnson said that "the safety and well-being of the people who use our products is our number one priority" and that it "strongly supports raising awareness of the signs and symptoms of this rare event."

covid-19 vaccine